logo
  

Sanofi : Sarclisa Combination Provides Unprecedented Median PFS In Relapsed Multiple Myeloma

French drug major Sanofi (SNYNF,SNY) said that Sarclisa (isatuximab) combination provided unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy.

The company noted that results from the Phase 3 IKEMA clinical trial evaluating Sarclisa in combination with carfilzomib and dexamethasone demonstrated a median progression free survival of 35.7 months, compared to 19.2 months in patients treated with dexamethasone alone.

Further analysis, following U.S. Food and Drug Administration recommendations on censoring rules, showed median progression free survival increased from 20.8 to 41.7 months when Sarclisa was added to carfilzomib and dexamethasone, the company said.

Sarclisa is a monoclonal antibody that targets a specific epitope on the CD38 receptor on multiple myeloma cells. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT